FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Report Finds Troubling Drug Imports for Weight Loss

Partnership for Safe Medicines releases a new report finding suspicious, unauthorized, and illegal ingredients for popular diabetes and obesity inject...

latest-news-card-1

2024 Device Recalls Up, Drug Recalls Down: Sedgwick

The Sedgwick full-year recall report for 2024 shows medical device recalls increasing and drug recalls decreasing.

latest-news-card-1
Medical Devices

Becton Dickinson Recalls ChloraPrep Lot

Becton Dickinson recalls one lot of ChloraPrep clear 1 mL applicators due to fungal contamination concerns.

latest-news-card-1
Human Drugs

Disappointing Data on Supernus Depression Drug

Supernus Pharmaceuticals says its Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically signific...

latest-news-card-1
Human Drugs

Expanded Access to TICE BCG Substitute

FDA approves an ImmunityBIO expanded access program for recombinant BCG to help address a BCG shortage in treating bladder cancer.

latest-news-card-1

What Happens to FDA in a Budget Shutdown?

Hyman, Phelps & McNamara regulatory and medical device principal expert Richard Lewis uses his experience at FDA during the 2018-2019 government shutd...

FDA General

AdvaMed Urges HHS Reversal of FDA Staff Cuts

Advamed president Scott Whitaker writes HHS to urge a reversal of staff cuts at CDRH to avoid a negative impact on patient care.

latest-news-card-1
Human Drugs

FDA Refusal to File Wakix sNDA

FDA refuses to file a Harmony Biosciences Wakix sNDA to treat excessive daytime sleepiness due to idiopathic hypersomnia.

latest-news-card-1
Human Drugs

AGs Seek FDA Actions on Counterfeit GLP-1 Drugs

A bipartisan coalition of 37 state Attorneys General call on FDA to take enforcement actions against online sellers of counterfeit versions of popular...

latest-news-card-1
Human Drugs

Multiple Violations at Jagsonpal Pharmaceuticals

FDA warns Indias Jagsonpal Pharmaceuticals about CGMP deviations and other violations in its manufacturing of active pharmaceutical ingredients.